(Q38153456)

29 August 2017

PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia (English)

1 reference

29 August 2017

1 reference

1 reference

2

John J P Kastelein

1 reference

29 August 2017

Shirya Rashid

1

1 reference

29 August 2017

18 October 2013

1 reference

Expert Review of Cardiovascular Therapy

29 August 2017

1 reference

29 August 2017

11

1 reference

29 August 2017

11

1 reference

29 August 2017

1567-1577

1 reference

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010

29 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Economic consequences of the obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Obesity, Metabolic Syndrome, and Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Abdominal obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Cardiovascular disease under the influence of excess visceral fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

21 January 2018

Obesity and dyslipidemia

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

The role of non-HDL cholesterol in risk stratification for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Diabetic dyslipidaemia: from basic research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Obesity and atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Genetic and metabolic determinants of plasma PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Unexpected roles for PCSK9 in lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

A family of tissue-specific resistin-like molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Serum Resistin (FIZZ3) Protein Is Increased in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Correlation between serum resistin level and adiposity in obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Resistin is an inflammatory marker of atherosclerosis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Plasma resistin levels correlate with determinants of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Triglycerides: a case for treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

A quantitative analysis of fish consumption and coronary heart disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Gene therapy for lipoprotein lipase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Microsomal transfer protein inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Lipids. Antibodies against PCSK9--a new era of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Anti-PCSK9 therapies for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

PCSK9: an emerging target for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2013.839204

10.1586/14779072.2013.839204

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24134510